Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Orthopaedics
  • Orthopaedics News
  • Olokizumab Outperforms...

Olokizumab Outperforms Placebo in RA patients on maintenance Methotrexate: NEJM

Written By : Dr. Kamal Kant Kohli Published On 29 Aug 2022 2:30 AM  |  Updated On 29 Aug 2022 7:48 AM
Olokizumab Outperforms Placebo in RA patients on maintenance Methotrexate: NEJM
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

VIENNA: Patients with rheumatoid arthritis taking maintenance methotrexate respond better to olokizumab than to a placebo and non-inferior to adalimumab states a research study published in The New England Journal of Medicine.

About 5 out of every 1000 persons develop rheumatoid arthritis (RA), which can cause significant joint damage and disability. The pathophysiology of rheumatoid arthritis is influenced by the cytokine interleukin-6. Olokizumab is a humanized monoclonal antibody that is being studied for the treatment of rheumatoid arthritis. It specifically targets the interleukin-6 cytokine.

"Adalimumab monotherapy is not a recommended course of treatment for rheumatoid arthritis since studies have indicated that adalimumab plus methotrexate is more effective than adalimumab alone", asserted the authors.

The researchers aimed to compare subcutaneous olokizumab (UCB) to adalimumab and placebo in terms of the safety and effectiveness of treating RA patients who are already taking Methotrexate.

For this objective a phase 3, multicenter, double-blind, parallel-group, randomized, placebo- and active-comparator controlled trial was carried out by the authors which included a total of 1643 patients. From May 2016 to November 2019, the study was carried out at 209 locations across the United States, the United Kingdom, continental Europe, South Korea, Taiwan, and Latin America. Olokizumab 64 mg subcutaneous injections were given to 464 patients randomly assigned at 2:2:2:1 ratio, followed by olokizumab 64 mg subcutaneous injections every 4 weeks given to 479 patients, adalimumab 40 mg subcutaneous injections every 2 weeks administered to 462 individuals, or a placebo subcutaneous injection given to 243 subjects every 2 weeks.

Patients had to meet the American College of Rheumatology-EULAR 2010 updated classification criteria for active RA and be at least 18 years old to be included. By week 12, the ACR20 or greater improvement was the study's primary efficacy goal. Secondary endpoints included noninferiority of each olokizumab dose to adalimumab regarding the ACR20 response at week 12, the proportion of patients with a DAS28 based on C-reactive protein levels of less than 3.2 at week 12, decrease in the Health Assessment Questionnaire-Disability Index score from baseline to week 12, ACR50 responses at week 24, and a Clinical Disease Activity Index score of 2.8 or less at week 24.

Key findings of the study:

  • At week 12, an ACR20 response was seen in 44.4% of patients who received placebo, 70.3% of patients who received olokizumab every two weeks, 71.4% of patients who received olokizumab every four weeks, and 66.9% of patients who received adalimumab (P<0.001 for the superiority of each olokizumab dose to placebo).
  • In terms of the proportion of patients who had an ACR20 response at week 12, both olokizumab doses were noninferior to adalimumab.
  • 70% of the patients who got olokizumab experienced adverse events, the most frequent of which were infections.
  • 3.8% of patients taking olokizumab every two weeks and 5.1% of those receiving it every 4 weeks had antibodies against the medication.

"To ascertain the effectiveness and safety of olokizumab in patients with rheumatoid arthritis, larger and longer trials are necessary", writes the authors.

The researchers concluded that in terms of an ACR20 response at week 12, olokizumab with methotrexate surpassed placebo plus methotrexate and was comparable to the combination of adalimumab and methotrexate.

REFERENCE

Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group; CREDOZ Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. PMID: 36001712.

olokizumabAdalimumabplacebomonotherapyrheumatoid arthritismethotrexateThe New England Journal of Medicinecytokineinterleukin-6monoclonal antibody
Source : The New England Journal of Medicine
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

Aspirin in Primary Prevention- When to Consider?

Aspirin in Primary Prevention- When to Consider?

View All

Journal Club Today

Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction Patients

Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction...

View All

Health News Today

Health Bulletin 21/ May/ 2025

Health Bulletin 21/ May/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok